Earth Science Tech Inc. (OTC: ETST) reported third fiscal quarter 2026 revenue of $8.4 million, representing a 14.1% year-over-year increase. The strategic holding company demonstrated improved operational efficiency with gross margin expanding to 76.3% from 69.2% in the previous comparable period. The company's gross profit reached $6.4 million during the quarter ended December 31, 2025, reflecting this margin improvement. This performance highlights what the company describes as improved operating leverage across its portfolio as it transitions toward what it calls a more shareholder-focused public company model.
Concurrently, ETST announced governance reforms and cost initiatives expected to generate approximately $1.4 million in annualized savings. These measures are projected to contribute to over 40% net income growth, signaling what the company characterizes as a new era of disciplined growth focused on expanding margins and optimizing cash generation. The financial results and strategic initiatives announced by Earth Science Tech Inc. represent a significant shift in the company's approach to growth and governance. The combination of strong quarterly performance with structural reforms aimed at cost reduction suggests a comprehensive strategy to enhance shareholder value through both operational excellence and organizational efficiency.
For investors and market observers, these developments indicate a company in transition, moving from acquisition-focused growth to margin optimization and disciplined financial management. The projected 40% net income growth trajectory, if achieved, would represent substantial improvement in profitability and could potentially reshape the company's market valuation and investor perception in the competitive holding company sector. The company's latest financial developments and updates are available through its newsroom at https://ibn.fm/ETST. This announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences and life sciences sectors. More information about the platform is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
